![]() Pre-existing subclinical lesions may become apparent following Efudix use.Īny severe skin discomfort during treatment with Efudix may be alleviated by the use of an appropriate topical steroid cream. Washing clothing and bedding may reduce product build-up but not totally remove it.Įxposure to UV-radiation (e.g natural sunlight, tanning salon) should be avoided. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Instruct patients not to smoke or go near naked flames - risk of severe burns. Occlusive dressing may increase inflammatory reactions of the skin. However these treatment effects sometimes be more severe and include pain, blistering and ulceration (see section 4.8). The clinical manifestation of response usually occurs in the second week of Efudix treatment. The normal pattern of response includes: early and severe inflammatory phases (typically characterised by erythema, which may become intense and blotchy), a necrotic phase (characterised by skin erosion) and finally healing (when epithelialisation occurs). Larger areas should be treated a section at a time. The total area of skin being treated with Efudix at any one time should not exceed 500 cm 2 (approximately 23 x 23 cm). Also care should be taken to avoid contact with mucous membranes or the eyes when applying the cream. The hands should be washed carefully after applying Efudix. In view of the lack of clinical data available, Efudix is not recommended for use in children. Many of the conditions for which Efudix is indicated are common in the elderly. Healing may not be complete until one or two months after therapy is stopped. Lesions on the face usually respond more quickly than those on the trunk or lower limbs whilst lesions on the hands and forearms respond more slowly. The usual duration of treatment for an initial course of therapy is three to four weeks, but this may be prolonged. Severe discomfort may be alleviated by the use of topical steroid cream. Treatment should be continued until there is marked inflammatory response from the treated area, preferably with some erosion in the case of pre-malignant conditions. The cream should be applied once or twice daily under an occlusive dressing where this is practicable. ![]() The cream should be applied thinly to the affected area once or twice daily an occlusive dressing is not essential. Date of first authorisation/renewal of the authorisation 6.6 Special precautions for disposal and other handling.4.7 Effects on ability to drive and use machines.4.5 Interaction with other medicinal products and other forms of interaction.4.4 Special warnings and precautions for use.4.2 Posology and method of administration.Show table of contents Hide table of contents
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |